Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6414932 | 0.87 | MAPT (0.47) | TSHRHTTL3MBTL1CYP3A4GAA | |
| SCHEMBL6413218 | 0.85 | HSD17B10 (0.47) | TSHRHTTL3MBTL1CYP3A4GAA | |
| SCHEMBL6410694 | 0.85 | TSHR (0.58) | TSHRHTTL3MBTL1CYP3A4GAA | |
| SCHEMBL6410700 | 0.83 | GAA (0.54) | TSHRCYP3A4GAATP53ALDH1A1 | |
| SCHEMBL6413424 | 0.83 | MAPT (0.46) | TSHRHTTL3MBTL1CYP3A4GAA | |
| SCHEMBL6412758 | 0.81 | ALDH1A1 (0.56) | TSHRHTTL3MBTL1CYP3A4GAA | |
| SCHEMBL2939041 | 0.81 | ALDH1A1 (0.54) | TSHRCNR1HTTL3MBTL1CYP3A4 | |
| SCHEMBL6413282 | 0.80 | HSD17B10 (0.48) | TSHRHTTL3MBTL1CYP3A4GAA | |
| SCHEMBL6412336 | 0.80 | TSHR (0.63) | TSHRHTTGAATP53ALDH1A1 | |
| SCHEMBL6412106 | 0.80 | GAA (0.46) | TSHRHTTL3MBTL1CYP3A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124614-A1 | 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | claimed |
| WO-2004004727-A1 | 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| US-20050124614-A1 | 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2004004727-A1 | 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124614-A1 | 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis | CASP3, BAX, BAD | TSHR 4878/4885CNR1 3410/4885HTT 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.